Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 08/6/18 → 08/6/20 |
Funding
- Boehringer Ingelheim Pharmaceutical: $14,064.00
A multi-centre, double-blind, parallel-group, randomized controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in patients with cognitive impairment due to
- Dubovsky, Steven (PI)
- Anker, Jeffrey (CoI)
Project: Research